|
Eckert & Ziegler SE / Key word(s): Alliance Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225 13-Nov-2024 / 08:54 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Berlin, 13 November 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a collaboration and licence agreement with the Australian-headquartered Telix Pharmaceuticals Limited (Telix) for the use of EZAG’s cyclotron-based technology to produce Ac-225. The contract entitles Eckert & Ziegler to milestone payments from Telix totaling up to € 20 million within approximately two years, as well as access to a higher availability of Ac-225. For Eckert & Ziegler the licence and collaboration agreement is an important step towards establishing the company as a major supplier of Ac-225 for the radiopharmaceutical industry. Eckert & Ziegler is already supplying Ac-225 and will be able to provide the market with significantly increased quantities of Ac-225 in GMP quality from 2025. Currently, Ac-225-based radiopharmaceuticals are under clinical investigation for various cancers, including prostate tumors, colorectal cancer, and leukemia. A substantial increase in the demand for Ac-225 is projected over the next decade, driven by its expanding clinical applications and the promising results seen in ongoing trials. Despite its therapeutic promise, sufficient quantities of Ac-225 remain scarce. Contact: End of Inside Information 13-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Opinion | How Should Health Plans Respond to Surging Interest in Weight Loss Drugs?
Klotz is Chief Medical Officer at a third-party health benefits administrator for self-insured employers. Since the NIH started measuring obesity prevalence in the U.S. 60
January 17, 2024